Apricus' stock rises on transdermal platform success; Echo gets patents for needle-free tech;

 @DamianFierce: Drugmakers are rethinking drug delivery methods for multiple sclerosis treatments. Report | Follow @DamianFierce

> Drug delivery firm Apricus Bio's stock has gone up nearly 30% over the last month, and that trend is likely to continue thanks to its NexACT delivery platform. News

> Echo Therapeutics ($ECTE) has secured patents for Symphony, its needle-free glucose monitor, and Prelude, the transdermal platform that makes it work. Story

> IntelGenx ($IGXT) got its OTC Markets listing upgraded, from OTCQB to OTCQX, OTC's highest tier. Release

> Fuse Science is touting positive study results for its transdermal delivery platform, eyeing partnerships in pharmaceuticals and consumer products. More

> Another firm has found a way to use chocolate as a platform to boost the efficacy of treatments. Item  

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.